Third Quarter Revenue Grew 7% to $18.4 Million  Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a precision medicine company bringing clarity to autoimmune disease,

CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the following investor conferences: Canaccord Genuity’s MedTech, Diagnostics and Digital

CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the market opens on Tuesday, November 10, 2026.

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million   Increased full-year revenue guidance to $72 - $75 million   CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc.

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference – Boston, MA Date: August 11, 2026

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026.

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical

Delivers record total revenue and AVISE(R) CTD average selling price CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive

Record full-year total revenue and AVISE ® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported